Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) FCF Margin (2016 - 2025)

Historic FCF Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 120.08%.

  • Viridian Therapeutics, Inc.\DE's FCF Margin rose 789485300.0% to 120.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 461.0%, marking a year-over-year increase of 649138300.0%. This contributed to the annual value of 77096.03% for FY2024, which is 181571700.0% down from last year.
  • Viridian Therapeutics, Inc.\DE's FCF Margin amounted to 120.08% in Q3 2025, which was up 789485300.0% from 100553.33% recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year FCF Margin high stood at 120.08% for Q3 2025, and its period low was 128804.17% during Q1 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median FCF Margin value was 52844.44% (recorded in 2023), while the average stood at 44139.27%.
  • The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's FCF Margin in the last 5 years was 789485300bps (2025), contrasted with its biggest fall of -659944400bps (2025).
  • Viridian Therapeutics, Inc.\DE's FCF Margin (Quarter) stood at 7765.89% in 2021, then plummeted by -320bps to 32640.95% in 2022, then tumbled by -62bps to 52844.44% in 2023, then tumbled by -93bps to 102008.33% in 2024, then surged by 100bps to 120.08% in 2025.
  • Its last three reported values are 120.08% in Q3 2025, 100553.33% for Q2 2025, and 128804.17% during Q1 2025.